Therapeutic Advances in Endocrinology and Metabolism · 2021 · 13 citations · 79 references
MedicineEndocrinologyUrologyAndrologyMeta-analysisProstate DiseaseBenign Prostatic HyperplasiaMetabolic SyndromeProstate DisordersProstate HealthBenign Prostatic EnlargementInternational Prostate Symptom ScoreLower Urinary Tract Symptom EvaluationLower Urinary Tract Symptom ScoringMale Lower Urinary Tract SymptomsMetabolic Syndrome AssociationsProstate Disease EpidemiologyProstate Size Assessment
Background: Metabolic syndrome (MetS) is defined by at least three of the following five criteria: blood pressure ⩾130/85 mmHg, fasting blood glucose ⩾5.6 mmol/l, triglycerides concentration ⩾1.7 mmol/l, waist circumference ⩾102 cm (for men), and high-density lipoprotein cholesterol concentration <1.03 mmol/l (for men). MetS has been associated with worse lower urinary tract symptoms (LUTS) and higher International Prostate Symptom questionnaire scores. Materials and Methods: MEDLINE, Cochrane, ClinicalTrials.gov, and SCOPUS were critically appraised for all peer-reviewed manuscripts that suitably fulfilled our protocol’s inclusion criteria established a priori. Meta-analytical and meta-regression calculations were performed in R using the Sidik–Jonkman and Hartung–Knapp random effects model and predefined covariates. Results: A total of 70 studies ( n = 90,206) were included in qualitative synthesis. From these, 60 studies focused on MetS and LUTS: 44 reported positive correlations, 5 reported negative correlations, 11 reported no association, and 10 studies focused on MetS and total prostate volume (TPV). MetS positively correlated with moderate LUTS [odds ratio (OR) = 1.56, 95% confidence interval (CI) = 1.35–1.80], severe LUTS (OR = 2.35, 95% CI = 1.82–3.03), overactive bladder (OAB; OR = 3.2, 95% CI = 1.6–5.8), and nocturia severity (OR = 2.509, 95% CI = 1.571–4.007) at multivariate analysis. A total of 30 studies ( n = 22,206) were included in meta-analysis; MetS was significantly associated with higher TPV (mean differences = 4.4450 ml, 95% CI = 2.0177–6.8723), but no significant predictive factors for effect sizes were discovered. Conclusion: Our meta-analysis demonstrates a significant association between the aggravating effects of MetS, which commonly coexists with obesity and benign prostate enlargement.
79
Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement
David Moher, A. Liberati, Jennifer Tetzlaff et al. · BMJ · 2009 · 83.3K citations · Full text
Harmonizing the Metabolic Syndrome
K. G. M. M. Alberti, Robert H. Eckel, Scott M. Grundy et al. · Circulation · 2009 · 14.7K citations · Full text
Assessing Bias in Studies of Prognostic Factors
Jill A. Hayden, Daniëlle van der Windt, Jennifer Cartwright et al. · Annals of Internal Medicine · 2013 · 3.1K citations
Prevalence and burden of overactive bladder in the United States
Walter F. Stewart, J. Van Rooyen, Geoffrey W. Cundiff et al. · World Journal of Urology · 2003 · 2.3K citations · Full text
Medicine, Internal Medicine, Urology +13